Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovalpituzumab tesirine in recurrent small cell lung cancer
NCT01901653Phase 2Completed
- Sponsor
- Stemcentrx
- Start
- Jul 2013
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rovalpituzumab tesirine in small cell lung cancer (SCLC), sponsored by Stemcentrx. Started Jul 2013; status: completed.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01901653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01901653.